Moderna (MRNA) option implied volatility elevated into investor meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/29/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK
6. S
7. ULTA
8. NVDA
9. GAP
10. DG

Go back to Moderna (MRNA) option implied volatility elevated into investor meeting

Evercore ISI Reiterates In Line Rating on Moderna (MRNA)

September 12, 2024 9:04 AM EDT

Evercore ISI analyst Cory Kasimov reiterated an In Line rating and $105.00 price target on Moderna (NASDAQ: MRNA).

The analyst comments "Moderna published a thorough R&D overview and also updated / extended its financial guidance ahead of todays R&D Day in NYC. On the pipeline front, the most market material update is probably the lower likelihood of an early filing for INT. On the financial... More

Morgan Stanley on Moderna (MRNA): 'we expect MRNA shares to trade off this morning'

September 12, 2024 8:26 AM EDT

Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $94.00 price target on Moderna (NASDAQ: MRNA)

The analyst comments "This morning MRNA provided updates on portfolio prioritization and new guidance ahead of the company's R&D day. MRNA plans to break even in... More

Jefferies Reiterates Buy Rating on Moderna (MRNA)

September 12, 2024 8:07 AM EDT

Jefferies analyst Michael Yee reiterated a Buy rating and $120.00 price target on Moderna (NASDAQ: MRNA).

The analyst comments "

Ahead of MRNA's R&D update this morning, they announced several updates with key being they plan to cut R&D spend though the bulk of the cut of $1.1B won't be until 2027. This now delays profitability until 2028 (vs prior guidance of 2026). 2025 revenue guidance is now $2.5-3.5B and below consensus of $3.8-4B too.... More